Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-11 of 11 for your search:
Cancer Type/Condition:
Skin cancer, melanoma
Stage/Subtype:
stage I melanoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Complete Lymph Node Dissection or Observation in Treating Patients With Localized Melanoma and Sentinel Node Metastasis Who Have Undergone Sentinel Lymphadenectomy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
JWCI-MORD-LM/SL-CLND-1102
, NCT00389571
2.
Lovastatin in Treating Patients at High Risk of Recurrent Melanoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCIRVINE-UCI03-1-01
, UCI03-1-01, UCIRVINE-2006-4937, NCT00462280
3.
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
CINJ-3330
, NCT00161187
4.
Abraxane and Temodar Plus Genasense in Advanced Melanoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GM108
, NCT00409383
5.
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MCC-03740
, NCT00580320
6.
Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ALS-357-001
, NCT00701987
7.
Randomized, Double Blind, Placebo-Controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
NYU 05-409
, NCT00821652
8.
Effects of GM-CSF and/or Incomplete Freund's Adjuvant on Immune Cells at or Around the Tumor Site in Patients With Stage I or Stage II Melanoma
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
NCI
Protocol IDs:
UVACC-MEL-38
, UVACC-14499, UVACC-HIC-8380
9.
A Proof-of-Concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
Phase:
No phase specified
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GE-135-003
, NCT00565721
10.
Pilot Study of IFN a2b for Melanoma Patients
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
08-067
, NCT00871533
11.
Comparison of Standard of Care or Treatment on Protocol
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
INST 0813
, NCT01010334
Select All on Page
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
